Products
Pre-Made Simlukafusp Alfa Biosimilar, Fusion Protein targeting FAP fused with human IL2 (interleukin 2, IL-2): Recombinant therapeutic protein targeting DPPIV/FAPA/FAPalpha/SIMP for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-991
Pre-Made Simlukafusp Alfa Biosimilar, Fusion Protein targeting FAP fused with human IL2 (interleukin 2, IL-2): Recombinant therapeutic protein targeting DPPIV/FAPA/FAPalpha/SIMP is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Simlukafusp alfa (SIM; FAP-IL2v) is an interleukin-2 variant moiety fused to a human antibody against fibroblast activation protein-α (FAP). Simlukafusp alfa bind to FAP expressed on cancer-associated fibroblasts and mediates its accumulation in malignant lesions. Simlukafusp alfa retains binding affinity to IL-2 receptor βγ without binding to IL-2Rα resulting in activation of immune effector NK and CD8 T cells but not regulatory T cells. FAP-IL2v is designed to increase the pool of activated immune effector cells and is intended to be a combination partner to enhance the efficacy of cancer immunotherapies.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-991-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-991-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-991-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-991-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Simlukafusp Alfa Biosimilar, Fusion Protein targeting FAP fused with human IL2 (interleukin 2, IL-2): Recombinant therapeutic protein targeting DPPIV/FAPA/FAPalpha/SIMP |
| INN Name | Simlukafusp Alfa |
| Target | FAP |
| Format | Fusion Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
